Related Experiment Video

Updated: Jun 21, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

The Development of Novel Therapies for Rheumatoid Arthritis

Ling-Dong Quan1, Geoffrey M Thiele, Jun Tian

  • 1Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Expert Opinion on Therapeutic Patents
|July 7, 2009
PubMed

Insights

Rheumatoid arthritis (RA) treatments are advancing, particularly with new biologic disease-modifying anti-rheumatic drugs (DMARDs). Future growth in RA therapies is expected due to pathway discoveries and drug delivery innovations.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic, systemic inflammatory autoimmune disease affecting 0.5-1% of adults globally.
  • RA leads to joint destruction and significantly impairs quality of life.
  • Recent discoveries in RA pathogenesis have spurred the development of novel therapeutic strategies.

Purpose of the Study:

  • To review recent advancements in antirheumatic therapies for rheumatoid arthritis.
  • To discuss current RA treatment categories: NSAIDs, glucocorticoids, non-biologic DMARDs, and biologic DMARDs.
  • To highlight new drug candidates and their mechanisms of action from patent searches.

Main Methods:

  • Literature review using SciFinder Scholar and PubMed.
  • Evaluation of newly developed RA therapies.
  • Analysis of drug mechanisms, limitations, and emerging candidates from patent data.

Main Results:

  • Most therapeutic development over the past 20 years has focused on disease-modifying anti-rheumatic drugs (DMARDs), especially biologic DMARDs.
  • Current treatments encompass NSAIDs, glucocorticoids, non-biologic DMARDs, and biologic DMARDs.
  • New drug candidates and strategies are emerging from patent literature.

Conclusions:

  • Significant progress in RA therapy has been driven by advancements in DMARDs, particularly biologics.
  • Continued growth in RA treatment innovation is anticipated.
  • Discovery of new pathogenic pathways and improved drug delivery systems will likely shape future therapies.

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...